Paxalisib

Drug Overview

Paxalisib (formerly known in research as GDC-0084) is an advanced, experimental cancer medicine. It belongs to a highly specialized group of medicines known as Targeted Therapy or “Smart Drugs.” Unlike older chemotherapy that travels blindly through the whole body, paxalisib is designed to hunt down and block specific growth signals inside cancer cells. What makes paxalisib truly unique is its ability to easily pass through the brain’s protective shield (the blood-brain barrier), making it a major focus in brain cancer research. Because it is currently being tested in clinical trials, it is not yet available at local pharmacies.

• Generic Name: Paxalisib
• US Brand Names: None (Experimental drug)
• Drug Class: Dual PI3K/mTOR Inhibitor (Targeted Therapy)
• Route of Administration: Oral (Taken by mouth as a capsule)
• FDA Approval Status: Not FDA Approved. (It is restricted to clinical trials. However, the FDA has granted it special statuses, such as “Fast Track” and “Orphan Drug” designations, to help speed up its research for rare brain cancers.)

What Is It and How Does It Work? (Mechanism of Action)

Paxalisib is a Targeted Therapy designed to break the communication system of brain cancer cells. To understand how it works at the molecular level, it helps to look at two important cell networks: PI3K and mTOR.

You can think of the PI3K and mTOR pathways as the “gas pedal” for a cell. When these pathways are activated, they tell the cell to grow, multiply, and stay alive. In many types of brain tumors, genetic mistakes cause this gas pedal to get stuck in the “on” position.

Here is how paxalisib stops this:

• Crossing the Shield: The brain has a strict security system called the blood-brain barrier, which stops most cancer drugs from entering. Paxalisib is specially designed as a very small molecule that can slip right past this security guard and enter the brain tissue.
• The Dual Blockade: Once inside the brain tumor, paxalisib acts as a “dual inhibitor.” It attaches to both the PI3K proteins and the mTOR proteins at the exact same time.
• Stopping the Signal: By blocking both parts of the pathway, paxalisib completely takes the foot off the tumor’s gas pedal. Without these growth signals, the cancer cells stop dividing and go through a natural process of self-destruction (called apoptosis).

FDA-Approved Clinical Indications

Because paxalisib is an experimental medicine, it has not yet received full approval from the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general public use.

Oncological Uses (Investigational Only):

• Glioblastoma (the most common and aggressive type of adult brain cancer)
• Diffuse Intrinsic Pontine Glioma (DIPG) and other childhood brain tumors
• Brain metastases (cancer that has spread to the brain from other parts of the body, like the breast or lungs)
• Primary Central Nervous System Lymphoma (PCNSL)

Non-oncological Uses:

• None at this time.

Dosage and Administration Protocols

Because paxalisib is currently given only in clinical trials, the dose is determined by the specific rules of the study. The information below shows how it is most commonly given in recent adult brain cancer trials.

Note: Individual dosing is strictly controlled by clinical trial doctors and based on how safely the patient’s body processes the medicine.

Clinical Efficacy and Research Results

Recent clinical trials (running from 2020 through 2024) have tested paxalisib in patients with glioblastoma, a cancer that is notoriously hard to treat.

• Glioblastoma Studies (GBM AGILE): In a major Phase 2/3 trial called GBM AGILE, paxalisib was tested in patients with newly diagnosed glioblastoma who had a specific genetic profile (unmethylated MGMT). While the drug did not achieve a massive breakthrough for all patients, data reported in 2024 showed promise. Patients taking paxalisib lived an average of roughly 14.5 to 15.5 months, compared to about 11.9 months for those on older standard treatments.
• Brain Metastases: In Phase 2 trials for patients whose breast cancer had spread to the brain, paxalisib successfully crossed into the brain tumors. It helped shrink or stabilize the brain tumors in some patients who had mutations in the PI3K pathway.
• Childhood Brain Cancers: Because of its unique ability to cross the blood-brain barrier, it is actively being tested for DIPG, a devastating pediatric brain tumor, showing signs that it can reach the tumor safely.

Safety Profile and Side Effects

Like all powerful cancer medicines, paxalisib can cause side effects. Because the PI3K and mTOR pathways are also used by the body to manage blood sugar and healthy skin, blocking them can cause specific issues.

Black Box Warning:

There is currently no FDA “Black Box Warning” because the drug is experimental and unapproved.

Common Side Effects (Occurs in >10% of patients)

• High blood sugar (Hyperglycemia) – This is the most common side effect.
• Feeling very tired or weak (Fatigue)
• Skin rashes
• Mouth sores or swelling (Stomatitis)
• Upset stomach (Nausea) and loose stools (Diarrhea)

Serious Adverse Events

• Severe Hyperglycemia: Blood sugar can spike to dangerous, diabetes-like levels, requiring immediate medical treatment.
• Liver Stress: Elevated liver enzymes, meaning the liver is inflamed or working too hard.
• Lung Inflammation (Pneumonitis): A rare but serious non-infectious swelling of the lungs that can cause severe shortness of breath.

Management Strategies

• For High Blood Sugar: Trial doctors require frequent blood sugar checks. If glucose levels rise, the patient is often prescribed common diabetes pills (like Metformin) to keep their blood sugar safe while continuing the cancer drug.
• For Rashes and Mouth Sores: Patients are given steroid creams for rashes and special gentle mouthwashes to soothe the gums.
• For Liver and Lung Safety: Routine blood tests and symptom checks are mandatory. If a patient develops a new dry cough or high liver enzymes, the drug is paused so the body can heal.

Research Areas

Research into paxalisib touches on an important area of regenerative oncology: targeting “cancer stem cells.” In glioblastoma, a small group of stubborn cells (called glioma stem cells) often survive standard radiation and chemotherapy. These stem cells are the reason brain tumors almost always grow back. Scientists have discovered that these glioma stem cells rely heavily on the PI3K/mTOR pathway to stay alive. By using paxalisib to shut down this specific pathway deep inside the brain, researchers hope to permanently destroy these hidden cancer stem cells, preventing the tumor from rebuilding itself in the future.

Patient Management and Practical Recommendations

Patient safety is the absolute priority in any clinical trial. Healthcare teams follow strict rules to protect patients taking paxalisib.

Pre-treatment Tests to be Performed

• Metabolic Panel & HbA1c: A thorough check of fasting blood sugar and average blood sugar levels to ensure the patient does not have uncontrolled diabetes.
• Liver and Kidney Function: Blood tests to confirm the body’s filters are healthy.
• Genetic Tumor Testing: A biopsy check to see if the tumor has the specific PI3K mutations that the drug targets.

Precautions During Treatment

• Daily Blood Sugar Monitoring: Patients will likely need to check their blood sugar at home using a standard finger-prick monitor.
• Sun Protection: Drugs that affect the PI3K pathway can make the skin very sensitive, leading to bad rashes if exposed to too much sun.

“Do’s and Don’ts” List

• DO take the capsule at the exact same time every day to keep a steady amount of medicine in your brain.
• DO tell your doctor immediately if you feel extremely thirsty, need to urinate constantly, or have blurry vision, as these are signs of high blood sugar.
• DO maintain good oral hygiene, using a soft toothbrush to prevent painful mouth sores.
• DON’T crush, chew, or open the capsules; they must be swallowed whole.
• DON’T start any new vitamins, herbal supplements, or over-the-counter medicines without asking your trial doctor, as they may dangerously interact with the experimental drug.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Paxalisib (GDC-0084) is an investigational drug and is not approved by the FDA, EMA, or other global regulatory bodies for commercial use outside of clinical trials. Always consult with your oncologist, neurologist, or a qualified healthcare provider regarding your specific medical condition, clinical trial eligibility, and available, approved treatment options.